Asston Pharmaceuticals Ltd. (APL) — Tipsheet https://tipsheet.markets/company/apl/ Every Tipsheet Editorial note covering Asston Pharmaceuticals Ltd. (APL), newest first. Grounded in BSE/NSE primary-source filings. en-in Fri, 03 Jul 2026 15:50:15 GMT Asston Pharma to raise ₹27.7 cr via preferential issue, 28% dilution https://tipsheet.markets/apl-asston-pharma-to-raise-27-7-cr-via-preferential-issue-28-dilution-118537/ https://tipsheet.markets/apl-asston-pharma-to-raise-27-7-cr-via-preferential-issue-28-dilution-118537/ Thu, 02 Jul 2026 18:26:43 GMT The nano-cap pharma company is selling a 28% stake to non-promoter investors, including a 12% block to Vijay Rathee, in a deal that could reshape control and pricing. The nano-cap pharma company is selling a 28% stake to non-promoter investors, including a 12% block to Vijay Rathee, in a deal that could reshape control and pricing.

What’s new

  • Board approved preferential issue of 24.1L shares at ₹115 each, raising ₹27.72 cr.
  • Largest allottee Vijay Rathee to hold 12.06% post-issue; Vijaylaxmi Infra gets 7.16%.
  • Issue represents ~28% dilution; EGM set for 31 July for shareholder nod.

Why it matters

At a market cap of just ₹69 cr, this ₹27.72 cr infusion is over 40% of the company's value. Existing shareholders face severe 28% dilution, and the entry of a 12% holder changes governance. The cash could fund growth, but the price is control.

What we’re watching

  • Whether shareholders approve the issue at the 31 July EGM.
  • How the stock trades post-announcement given dilution and new investor entry.
  • Any specific utilisation plans for the ₹27.72 cr.

The full read

Asston Pharmaceuticals, a nano-cap with a market cap of ₹69 cr, is raising ₹27.72 crore by selling 24.1 lakh shares at ₹115 each to non-promoter investors. The sum is over 40% of the company's current market value. The dilution is steep: 28% of existing equity heads to new holders. Vijay Rathee alone will own 12.06% post-issue, and Vijaylaxmi Infra Projects gets 7.16%. The EGM is on 31 July; regulatory approvals are still pending. For a company with trailing ROE of 40.4% and low debt, the cash could be used to scale or for acquisitions. But at this price, existing shareholders are ceding a large chunk of control. The open question is whether the stock reprices lower to reflect the dilution or higher to reflect the capital.

Primary source: BSE · NSE

]]> Other Tipsheet Editorial